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were taken in a motorized water phantom using small 
detectors (Razor stereotactic diode and PFD, IBA Dosimetry). 
In addition, MLC transmission was measured using a Farmer 
ion chamber. MLC model parameters (transmission, offset, 
leaf tip width, tongue-and-groove) were optimized to 
maximize the agreement between measurements and 
calculations. Model assessment was performed using a set of 
highly intensity-modulated MLC geometrical patterns, 
designed to enhance tongue-and-groove, transmission and 
offset/leaf-tip effects. For those fields, planar dosimetry was 
carried out with GafChromic EBT3 films. Clinical validation 
was performed evaluating TG-119 cases along with 25 DMLC 
and 10 VMAT clinical plans. Plan-specific quality assurance 
was performed with a 2D-array (MatriXX, IBA Dosimetry) and 
gamma-index metric was used to assess the agreement 
between planned and measured dose distributions. A 
2%/2mm criterion was used with both local (LN) and global 
(GN) normalization. 
 
Results: Optimized MLC parameters were: transmission 
0.018, position-offset 0.04cm, tongue-and-groove 0.05cm, 
leaf tip width 0.3cm. Average and standard deviation (SD) 
values of gamma index pass-rates were: for geometrical 
patterns: 92.8%, SD=5.1%(LN); 95.5%, SD=2.5%(GN). For TG-
119 plans: 97.1%, SD=4.4%(LN); 99.7%, SD=0.7%(GN). For 
DMLC clinical plans: 97.0%, SD=3.7% (LN); 98.8%, 
SD=2.6%(GN). For VMAT plans 90.1%, SD=4.0% (LN); 96.5%, 
SD=2.1% (GN). Critical regions dominated by tongue-and-
groove and rounded-leaf-tip effect showed a very good 




Conclusion: Results demonstrate the followed procedure 
leads to a proper optimization of the MLC model in 
RayStation, leading to clinically acceptable gamma index 
pass-rates. The needed additional measurements can be 
easily integrated as a subset of the standard measurements 
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Purpose or Objective: To compare dose-volume metrics 
calculated with the four-dimensional (4D) Monte Carlo (MC) 
and three-dimensional (3D) dose evaluation systems in 
dynamic tumor tracking (DTT) irradiation for lung or liver 
tumors. 
 
Material and Methods: Twenty patients with lung tumors and 
15 patients with liver tumors who underwent DTT irradiation 
using a gimbal-mounted linac were enrolled in this study. 
During computed tomography (CT) simulation, 4DCT under 
free breathing and exhale breath-hold CT were performed. 
Planning target volume (PTV) for DTT was calculated using 
the gross tumor volume (GTV) delineated on a reference CT 
scan (exhale phase in the 4DCT or exhale breath-hold CT) by 
adding asymmetric margins to compensate for possible errors 
due to the DTT. The 6 to 9 non-coplanar ports of the 6-MV X-
ray were set to each PTV. Doses were calculated for the 
reference CT using a commercially available treatment 
planning system (TPS). At the same time, 4DMC dose 
evaluation was performed for 10 respiratory phases of 4DCT 
using an in-house dose calculation system based on the MC 
algorithm, considering the gimbal rotation. The doses 
calculated for 10 phases were accumulated using deformable 
image registration software for the lung tumor patients, 
whereas mean values of the dose-volume metrics were 
evaluated for the liver tumor patients. The difference 
between the doses calculated with 4DMC (4D doses) and 
those calculated for the reference CT scan with TPS (3D 
doses) were investigated for the following dose-volume 
metrics: the percentage of dose that covers 95% of the GTV 
(GTV D95), the max dose received by the spinal cord (Cord 
max), the percentage of lung volume that received more 
than 20 Gy and 5 Gy irradiation (Lung V20 and Lung V5, 
respectively) in patients with lung tumors, and the mean 
dose and percentage of liver volume that received more than 
20 Gy irradiation (Liver mean and Liver V20, respectively) in 
patients with liver tumors. 
 
Results: The mean values of the dose-volume metrics for the 
4D doses were as follows: 94.1% (range, 83.8–99.7%) GTV D95, 
9.7 Gy (range, 1.8–22.0 Gy) Cord max, 4.9% (range, 1.9–
13.7%) Lung V20, 19.2% (range, 7.2–30.7%) Lung V5, 10.0 Gy 
(range, 5.2–15.2) Liver mean,15.5% (range, 8.2–27.7%) Liver 
V20 The mean differences in the dose-volume metrics for the 
3D and the 4D doses were as follows: 0.5% (range, -7.4–4.8%) 
GTV D95, 0.1 Gy (range, -2.5–1.8 Gy) Cord max, 0.1% (range, 
-0.8–1.4%) Lung V20, 0.3% (range, -1.6–2.1%) Lung V5, 0.1 Gy 
(range, -1.6–1.1 Gy) Liver mean, and -1.0% (range, -1.7–3.1%) 
Liver V20. There were no statistical significant differences in 
these dose-volume metrics evaluated by paired t-test. 
 
Conclusion: The 3D doses calculated with TPS for the target 
tumor and organs at risk were almost equal to those 
calculated with 4DMC. 3D dose could be used as a 
substitution for 4DMC calculation. However, the dose to the 
spinal cord was underestimated by a maximum of 2.5 Gy. 
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Purpose or Objective : Unwanted peripheral doses (PD) from 
external beam radiotherapy (RT) are associated with 
increased incidence of second cancers. PD estimations after 
RT are becoming highly relevant due to the larger cancer 
incidence as well as survival rates. Additionally, an accurate 
knowledge of out-of-field doses is of importance when 
treating children, pregnant patients and those with 
implantable electronic devices [1]. Our group has developed 
a novel peripheral photon dose (PPD) model [2] which 
includes intensity modulated treatments. This model 
estimates out-of-field doses (i.e., beyond the commercial 
TPS limits -around 10 cm from the field edge) received by 
individual patients undergoing any RT isocentric technique.  
The aim of this work was the experimental validation of the 
model in a number of points inside the Alderson Radiation 
Therapy phantom (ART) irradiated with an IMRT prostate 
plan. This exercise is part of the process toward the 
implementation of the model onto a commercial TPS. 
 
Material and Methods: A Siemens Primus linac was used to 
deliver a 6 MV prostate IMRT treatment (896 MU and 7 
incidences, equivalent to 2 fractions of the treatment). TLD-
100 pairs of dosimeters were inserted at phantom holders, 
placed outside the 1% isodose as shown in the coronal plane 
of the figure. Positions were selected as being representative 
of cancer-at-risk organs. TLD-100 readings were converted 
into doses, through a calibration factor which considers the 
spectral condition outside the field, and then compared to 
PPD model estimates [2]. Measured leakage outside the field 
resulted 4 μGy/MU. Peripheral photon equivalent dose (PPED) 
to organs was also computed using PERIPHOCAL [2] (a 
MATLAB® GUI piece of software which considers a basic 
patient model with scaled dimensions from Cristy phantom 
[3]).  
 
Results: Plot at the figure depicts the estimated and 
measured photon equivalent doses (mSv) at 11 points for 
studied case (identified on the coronal plane of the 
phantom). Uncertainty Range (UR) corresponds to ±2 mSv and 
the error bars represent the ±6 % global uncertainty 




Conclusion: Validation of a PPD calculation model [2] has 
been carried out in an Alderson phantom for an IMRT prostate 
treatment using TLD-100 detectors. Very good agreement has 
been found between the model and the experimental 
measurements. However, bigger differences have been found 
between dose to points and PPED to organs, which might 
suggests that the mathematical phantom and/or the 
escalation model used for estimating organ 
location/dimensions are not properly mimicking the anatomy 
of the Alderson phantom. This issue deserves further 
investigation before implementing the dose-to-organ model 
onto a commercial TPS. 
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Purpose or Objective: Flattening filter free (FFF) beams 
generated by medical linacs are today clinically used for 
stereotactical treatments, thanks to their very high dose rate 
(up to four times the dose rate of the common flattened 
beams). Such beams differ from the standard flattened 
beams (FF) in the profile shape, that is strongly peaked on 
the beam central axis. However, FFF beams are not standard 
in terms of the parameters describing the field 
characteristics. Definitions of new parameters as unflatness 
and slope for FFF beams have been proposed, based on a 
renormalization factor for FFF profiles. With those factors 
the FFF dose fall-off at the field edge is superimposed with 
the corresponding (in nominal energy) flattened profile 
commonly normalized to 100% at the beam central axis. The 
present study aims to provide the renormalization factors for 
FFF beams of 6 and 10 MV generated by Varian TrueBeam and 
by Elekta Versa HD linacs. Estimation of the values of the 
new parameters (unflatness and slope) for the two units are 
also given. 
 
Material and Methods: Dosimetric data from two Varian 
TrueBeam and two Elekta Versa HD linacs, all with 6 and 10 
MV nominal accelerating potentials, FF and FFF modes have 
been collected. Renormalization factors were estimated 
according to Fogliata et al. procedure (Med.Phys. 2012,39) 
with the third derivative method, and parameters of 
RenormFactor=(a+b*FS+c*depth)/(1+d*FS+e*depth) have been 
fitted for FFF beams of both units and energies. Unflatness 
and slope parameters were computed. Dosimetric differences 
as beam penetration and surface dose were also assessed. 
 
Results: Renormalization factors are summarized in the 




Once the FFF profiles have been renormalized, the unflatness 
and slope were computed. As an example of unflatness 
parameter, for a 20x20 cm2 field, it was estimated in the 
range (from dmax to 30 cm depth) of 1.248-1.317, and 1.304-
